Orthopedic Oncology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics, each sourced and dated) with generalizations and synthesized opinion about culture and "who fits." It's here to help you get curious and go find out for yourself, not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-08-04.

Also called: musculoskeletal oncology, MSK oncology, orthopedic oncology, sarcoma surgery, limb salvage. A 1-year fellowship entered after an orthopedic surgery residency, not a residency you match into from medical school. Organ systems: bone and soft tissue, when a tumor is growing in them.

Subspecialty fellowship of Orthopedic Surgery.

The 30-second version

Orthopedic oncology is the smallest subspecialty in orthopedic surgery and the one that decides whether a limb stays on. Its defining operation is limb salvage: removing a bone or soft tissue sarcoma with a wide margin and then rebuilding what is left with a megaprosthesis, a bone allograft, or a vascularized graft, so that a nineteen-year-old with osteosarcoma of the distal femur walks out with a leg rather than an amputation. That shift, from amputation as the standard to limb salvage in the large majority of cases, happened within living memory and was driven by effective chemotherapy rather than by surgical technique alone, which tells you how tightly this field is bound to medical oncology. The volume, though, is not sarcoma. Primary bone tumors are rare, and most of what an orthopedic oncologist actually operates on is metastatic bone disease: breast, prostate, lung, kidney, and thyroid cancers that have spread to bone and need stabilization before or after a fracture. The trade at the center of the field: the most technically ambitious reconstruction in orthopedics and its clearest oncologic stakes, in a subspecialty that is small, academic, and near the bottom of orthopedic compensation.

Quick dashboard (details and sources below)


Training after med school	6 years (5 yr orthopedic surgery residency + 1 yr musculoskeletal oncology fellowship)
Total from college start	~14 years (4 undergrad + 4 med school + 5 residency + 1 fellowship)
Training chain	Med school (4) → Orthopedic Surgery (5 yr) → 1 yr musculoskeletal oncology fellowship (SF Match)
Competitiveness (as an orthopedic fellowship)	Low by volume, since the field is tiny and self-selecting, with programs concentrated at cancer centers ⟳
Typical full-time pay	No survey line. Parent orthopedics runs ~$610,000–$700,000 median; this subspecialty sits toward the bottom of it ⟳
Pay vs. parent (general orthopedics)	Below, and materially. Long cases, low volume, and near-total academic concentration ⟳
Lifestyle	Long operative days, heavy multidisciplinary load, and pathologic fracture as the urgent work ⟳
Burnout	No subspecialty figure; parent orthopedics is ~44%, among the lowest of all specialties on Medscape 2024 ⟳
% women	No published subspecialty figure; parent orthopedics ~6% practicing, ~24% of residents ⟳
DO / IMG accessibility	Gated behind orthopedics (of the 963 positions filled in the 2026 Match, 12.6% went to DO seniors, 14.0% counting DO graduates, and 1.0% to IMGs), and DO applicants are ranked lower at the fellowship stage ⟳

What they actually do

Metastatic bone disease is the volume, and this surprises people. Far more patients have cancer that has spread to bone than have a primary bone tumor, and stabilizing an impending or completed pathologic fracture is the most common operation in the field. Intramedullary nailing, endoprosthetic replacement, and cement augmentation are done to keep a patient with metastatic disease walking and out of pain for whatever time they have, which makes a large share of the practice palliative in intent and reconstructive in execution.

Primary bone sarcomas are the field's identity. Osteosarcoma and Ewing sarcoma in adolescents and young adults, chondrosarcoma in older patients, and the rarer entities. Treatment is chemotherapy, then wide resection, then reconstruction, with the surgical margin as the variable most under the surgeon's control and most predictive of local recurrence.

Soft tissue sarcomas are the other primary category, arising anywhere in the extremities or trunk, usually treated with radiation and wide excision, and often requiring plastic surgery for soft-tissue coverage afterward.

Reconstruction is where the technical ambition lives. Endoprosthetic megaprostheses replace whole segments of bone with a joint attached. Structural allografts use donor bone. Expandable prostheses in growing children lengthen as the child does. Rotationplasty, in which the lower leg is rotated 180 degrees so the ankle functions as a knee, remains the right answer for some young children and is one of the most striking operations in orthopedics.

Benign aggressive lesions round out the practice: giant cell tumor, osteoid osteoma, aneurysmal bone cyst, and the surveillance of the many incidentally discovered bone lesions that turn out to be nothing.

Representative procedures: wide resection of bone and soft tissue sarcoma · endoprosthetic reconstruction, including expandable implants in children · structural allograft and allograft-prosthetic composite reconstruction · rotationplasty · pelvic and sacral resection, among the largest operations in orthopedics · prophylactic and post-fracture stabilization in metastatic disease · radiofrequency ablation of osteoid osteoma · biopsy of suspicious bone and soft tissue lesions, which is a specific skill because a badly placed biopsy tract can cost a limb · amputation and rotationplasty when salvage is not possible.¹

A day in the life: long operative days, heavy clinic, and a great deal of conference. Sarcoma is managed by multidisciplinary tumor board, so orthopedic oncologists sit weekly with medical oncology, radiation oncology, radiology, and bone and soft tissue pathology, and the decisions are collective. Operative days are long, since a resection and endoprosthetic reconstruction can run most of a day. Clinic mixes new referrals of indeterminate lesions, long-term surveillance of sarcoma survivors, and metastatic patients needing stabilization decisions.

The referral role is distinctive. Orthopedic oncologists are the people other orthopedic surgeons call when a lesion looks wrong on an X-ray, and a substantial part of the job is telling a colleague not to biopsy something before sending it.

On call: moderate. Pathologic fracture in a metastatic patient is urgent, and spinal cord compression from metastatic disease is an emergency shared with spine surgery, but the elective work dominates.

The training path & time to completion

Medical school (4 yrs) → orthopedic surgery residency (5 yrs, integrated) → 1-year musculoskeletal oncology fellowship → practice.¹²

The residency is the hard gate, and it is among the most competitive in medicine: of the 963 positions filled in the 2026 Match, 12.6% went to DO seniors and 1.0% to IMGs, about ten matches.³ The parent orthopedic surgery profile covers it.
The fellowship is one year and matches through the separate SF Match, where orthopedic fellowships run rather than through the NRMP.²
There is no board. ABOS certifies subspecialties in only two areas, Orthopaedic Sports Medicine and Surgery of the Hand. A musculoskeletal oncologist practices under general ABOS certification with the fellowship as the credential.³
Total from the start of college: about 14 years.
Some trainees add a second year, and a few combine musculoskeletal oncology with an arthroplasty or trauma fellowship, because the reconstructive and fixation skills overlap heavily and a pure sarcoma practice is not available in most markets.

How competitive is it?

This is a small field, and its size is the main thing to understand about entering it. Musculoskeletal oncology has the fewest programs and positions of any orthopedic subspecialty, and training is concentrated at institutions with a sarcoma program, which is a limited set.

The applicant pool is correspondingly small and heavily self-selecting. Residents who want this generally know early, have research in it, and have a mentor.
The broader orthopedic fellowship picture applies. A 2025 JBJS Open Access study of 7,128 US-based applicants across 2012 to 2023 found equal match rates for men and women, at about 90% each, but a persistent gap by degree type, at a mean of 91% for allopathic graduates against 82% for osteopathic, concluding that osteopathic graduates are consistently ranked lower by orthopedic fellowship programs.⁴ Musculoskeletal oncology was not among the six subspecialties that study broke out, so treat this as the field-wide pattern rather than a subspecialty figure. ⟳
The real constraint is downstream. A sarcoma practice requires a referral base and a multidisciplinary program, which exist at a limited number of cancer centers. The number of jobs, not the number of fellowships, is what shapes this career.

The honest read. Attainable for a resident who genuinely wants it and has built toward it, with the meaningful risk being the job market rather than the match. Most graduates combine sarcoma work with general orthopedics, arthroplasty, or trauma, because a pure practice is rare.

Board: none specific. General ABOS certification in orthopedic surgery.³

Compensation — the robust version

No compensation survey isolates musculoskeletal oncology, and the field is small enough that one probably could not be constructed reliably. This reasons from the parent field and case mix.

The parent anchor. Orthopedic surgery runs roughly $610,000–$700,000 median total compensation and is frequently the highest-paid specialty in the country, and the percentile ladder the orthopedic profiles on this site carry — 25th percentile around $520,000, median around $703,000, 75th around $890,000, and 90th above $1.1 million — comes from an aggregator's directional planning model rather than from a licensed survey, and it is pending a replacement.³ ⟳

Musculoskeletal oncology sits toward the bottom of that distribution, and the mechanism is arithmetic rather than valuation. Orthopedic income scales with case volume and relative value units per operating hour. This subspecialty does the opposite of what that rewards:

The cases are long. A resection and endoprosthetic reconstruction can occupy most of a day, where an arthroplasty surgeon completes several replacements in the same time.
The volume is low, because primary sarcoma is rare and the referral base for it is limited.
A large share of the work is cognitive and unbillable, including tumor board, surveillance imaging review, and the consultative role of advising other surgeons about lesions they should not biopsy.
The jobs are academic. A sarcoma program needs medical oncology, radiation oncology, and specialist pathology alongside it, which means a cancer center, which means an academic salary. There is no private high-volume version of this field.

What offsets it. Most orthopedic oncologists carry a second practice, in arthroplasty, trauma, or general orthopedics, and that mixed practice is what makes the economics work. Metastatic bone disease stabilization is also higher-volume and better-reimbursed than sarcoma resection, and it is a growing share of the field as cancer survival improves.

Limited-data caveat: no MGMA, Doximity, or Medscape line for musculoskeletal oncology was located, and the positioning within orthopedics is a structural inference from case length, volume, and employment setting rather than a measured figure. The parent percentile ladder is not survey-based either, and is pending. Benchmark against academic orthopedic salary scales and ask specifically what proportion of the practice is expected to be non-oncologic. ⟳

Lifestyle

Operative days are long, and the reconstructions are among the most demanding physical and technical work in orthopedics.
The multidisciplinary load is heavy. Tumor board, sarcoma conference, and coordination with medical and radiation oncology are fixed weekly commitments, not optional extras.
Call is moderate, driven by pathologic fracture and metastatic cord compression rather than by trauma.
Academic structure shapes the week, with teaching, research, and administrative expectations attached to almost every job.
Geographic flexibility is poor. Sarcoma programs exist at a limited number of cancer centers. This is the field's most binding practical constraint, and it is the reason most graduates build a mixed practice.
Residency remains brutal regardless, as the parent profile documents.³

Lifestyle rating: 2/5. Long cases, heavy conference load, real call, and a narrow job map, offset by elective scheduling and the absence of a trauma-driven night burden.

Wellbeing — the part to take seriously

No musculoskeletal-oncology-specific wellbeing data exists. Inherit orthopedics at roughly 44% burnout, among the lower group despite the hours.³ ⟳

The emotional profile is unlike the rest of orthopedics and closer to oncology. Most orthopedic surgeons fix things and the patient gets better. This field treats cancer, much of it in adolescents and young adults, and a meaningful share of patients die of their disease. Osteosarcoma in a teenager is the field's signature case, and following that patient through chemotherapy, resection, reconstruction, and sometimes recurrence is a longitudinal oncologic relationship that no other orthopedic subspecialty carries.

The metastatic half carries a different weight. Operating to keep someone walking for the months they have left is palliative surgery, and judging when an operation is worth it, and when it is not, is a repeated and genuinely difficult judgment.

The compensating satisfaction is the limb. Preserving a functioning leg in a nineteen-year-old, where the alternative within living memory was amputation, is about as clear a professional good as surgery offers, and practitioners name it consistently.

The biopsy responsibility is a specific stressor. A poorly planned biopsy elsewhere can convert a salvageable limb into an amputation, and orthopedic oncologists spend real energy on prevention, education, and occasionally on managing the consequences of another surgeon's well-intentioned mistake.

Career longevity is reasonable, though the long, physically demanding reconstructions are harder to sustain late in a career than clinic-based work.

Who's in the field (demographics)

No published musculoskeletal-oncology-specific demographic data was located, which is unsurprising for a field this small. Inherit orthopedics, directionally.

Women: parent orthopedics runs about 6% women among practicing surgeons and roughly 24% of residents, the lowest proportion of any specialty in medicine.³ Across orthopedic fellowships, match rates do not differ by gender, at about 90% for both.⁴ ⟳
DO: parent orthopedics gave 12.6% of its 963 filled positions to DO seniors in 2026, 14.0% counting DO graduates, and at the fellowship stage osteopathic applicants matched at a mean of 82% against 91% for allopathic applicants across 2012 to 2023, with the study concluding that programs rank them lower.³⁴ ⟳
IMG: 1.0% of orthopedic residency positions, about ten matches a year of 963, so the pipeline is nearly closed upstream.³ ⟳
Underrepresented in medicine: no subspecialty figure. Orthopedic surgery has among the lowest URiM representation of any specialty and that is inherited whole. ⟳

Culture, personality & the online stereotypes

Who gravitates here: orthopedic residents who wanted the hardest reconstructions and were drawn to oncology. The field selects for people comfortable with long operations, with multidisciplinary decision-making rather than surgical autonomy, and with patients who may not survive. It is academic by construction and small enough that the community is national rather than local. As always, plenty of people in the field do not fit any single mold.

The stereotypes. Community perception rather than fact, each with a kernel and an unfair edge:

"The orthopedic surgeons who are actually oncologists." Broadly fair. The tumor board, the chemotherapy coordination, and the survival conversations are oncology, and the operating is orthopedics.
"Small field, small paycheck, big cases." Accurate on all three counts, and the field tends to answer with the limb-salvage argument rather than dispute it.
"Most of what they do is metastatic disease, not sarcoma." True, and it matters before you enter, since the identity of the field and the volume of the field are different things.
"Do not biopsy that, call them first." Not a stereotype so much as standing advice across orthopedics, and the field earns it.

What people say online (synthesized and paraphrased, not quotes): across trainee and physician forums, orthopedic oncology reads as the most respected and least chosen subspecialty in the field. The dominant recurring theme is the job market, with posters warning that pure sarcoma jobs are few, are academic, and are geographically fixed, and that almost everyone builds a mixed practice with arthroplasty or trauma. A second thread is compensation, described bluntly as the lowest in orthopedics for the longest cases. A third is the intellectual and emotional draw, described in unusually serious terms, with limb salvage in young patients the example reached for. A fourth is the biopsy-tract principle, repeated to residents constantly. The tone is admiring and cautionary at once.

Voices from the field. Paraphrased from published sources, with links to the originals:

A 2025 JBJS Open Access analysis of 7,128 US-based orthopedic fellowship applicants across 2012 to 2023 found equal match rates for men and women but a persistent gap by degree type, at 91% for allopathic against 82% for osteopathic applicants, and concluded that osteopathic graduates are consistently ranked lower by orthopedic fellowship programs.⁴
ABOS certifies only two orthopedic subspecialties, sports medicine and surgery of the hand, so musculoskeletal oncologists practice under general certification, the same structure the adult reconstruction profile documents for arthroplasty.³

Why people choose it / why people leave

Why choose it: limb salvage, which is among the clearest professional goods in surgery · the most technically ambitious reconstructions in orthopedics, including megaprostheses, allografts, and pelvic resections · genuine oncologic medicine alongside the surgery · multidisciplinary practice as a peer of medical and radiation oncology · a small enough field to know and be known in · the consultative role of being the person other surgeons call.

Why leave or avoid it: the lowest compensation in orthopedics for the longest cases · a narrow, academic, geographically fixed job market · a practice most people cannot do purely, so a second fellowship or a mixed practice is usually necessary · patients who die of their disease, including adolescents · heavy conference and unbillable cognitive load · no subspecialty board.

Best fit if: the biggest reconstructions are what you want · you are drawn to oncology as much as to orthopedics · you can be flexible about geography · you want an academic career · you can carry the loss of young patients.

Not for you if: you want orthopedics' income, which is elsewhere in the specialty · you need geographic freedom · you want surgical autonomy rather than committee decision-making · high-volume efficient operating is what appeals to you · losing patients would be hard to sustain.

The FLI angle — Orthopedic oncology for first-gen, low-income & immigrant students

Where it fits FLI realities well:

PSLF fits this path better than any other orthopedic subspecialty, precisely because the jobs are at academic cancer centers, which are qualifying nonprofit employers. Five residency years and a fellowship year count toward the 120 payments. In a specialty where nearly every other subspecialty pushes you toward private practice and away from forgiveness, this one does the opposite, and given the lower salary that matters.
The income is still excellent in absolute terms. Even at the bottom of orthopedics, this sits well above most of medicine.³
The fellowship is attainable for a resident who builds toward it, since the field is small and self-selecting rather than fought over.
The metastatic half of the practice serves patients across every income level, and continuity with people facing an incurable illness is work where trust matters more than technique.

Risks to name honestly:

The residency is one of the least FLI-accessible gates in medicine: 12.6% of its 963 filled positions to DO seniors, 1.0% to IMGs, and 6.8% women among practicing orthopedic surgeons.³ Research, away rotations, and connections decide it, and all cost money.
The DO disadvantage continues at the fellowship stage, with osteopathic applicants matching orthopedic fellowships at 82% against 91% and programs ranking them lower.⁴ Know that before assuming the hard part ends at the match.
This is the largest within-specialty pay sacrifice in orthopedics, and it comes with the narrowest job map. If your family's position depends on your income, model that against arthroplasty or sports medicine, which are reached from the same residency.
Geography is genuinely constrained. Sarcoma programs are at cancer centers. If living near family in a particular place is non-negotiable, this field probably cannot accommodate it.
Plan for a mixed practice from the start, since almost everyone does one, and it is better to choose the second component deliberately than to accept whatever the first job requires.

Bottom line for FLI: the most meaningful work in orthopedics attached to its smallest paycheck and its narrowest map, with a PSLF fit that does more work here than anywhere else in the specialty. If you can get through the orthopedic match and you want to spend a career saving limbs, this is a real and reachable path. Decide the geography question and the second-fellowship question before you commit, rather than discovering both in your first job search.

Fun facts

Limb salvage replaced amputation within living memory, and the change was driven as much by effective chemotherapy as by surgical technique.
Rotationplasty rotates the lower leg 180 degrees so the ankle works as a knee joint. It looks startling and it functions better than an above-knee amputation for some young children.
Expandable prostheses grow with the child. A megaprosthesis implanted in a growing patient can be lengthened as they develop, avoiding repeat major reconstruction.
The most common operation in the field is not sarcoma surgery. Stabilizing metastatic bone disease outnumbers primary bone tumor resection by a wide margin.
A biopsy in the wrong place can cost a limb. Contaminating an uninvolved compartment converts a salvageable tumor into an amputation, which is why the field asks to be called before anyone takes tissue.
There is no board in it. ABOS certifies only orthopedic sports medicine and surgery of the hand.

Sources

Clinical scope and fellowship content — primary bone and soft tissue sarcoma resection and reconstruction, metastatic bone disease stabilization, benign aggressive lesions, endoprosthetic and allograft reconstruction, rotationplasty, pelvic and sacral resection, and the biopsy-planning principle. Composite of published US musculoskeletal oncology fellowship curricula and Musculoskeletal Tumor Society materials. (accessed 2026). ↩ ↩²
Match structure. Orthopedic fellowships, including musculoskeletal oncology, are matched through the separate SF Match rather than the NRMP. SF Match Orthopaedics Fellowship (https://sfmatch.org/specialty/orthopaedics-fellowship/Overview), accessed 2026. ⟳ ↩ ↩²
Parent-field figures for orthopedic surgery. Compensation, training structure, and competitiveness: typical comp ~$610k–$700k median, with a percentile ladder of 25th ~$520k, median ~$703k, 75th ~$890k, and 90th above $1.1M, frequently the highest-paid specialty; 5-year integrated residency with more than 90% of residents doing a fellowship; among the hardest specialties to match. Those are carried from the orthopedic surgery, adult reconstruction and orthopedic sports medicine profiles on this site, which are cross-references rather than sources; the survey figures are cited on those pages. Swept 2026-08-17: this footnote and the compensation section both labeled the four percentiles "MGMA." They come from FastRVU's orthopedic-surgery income guide, which says of itself that it presents "a directional planning model centered on $703,000 as an illustrative reference point, not a licensed survey result" and that its percentile table "is not a licensed MGMA table." The orthopedic surgery profile's own [^10] carries the full record. The false attribution is removed here; the figures themselves rest on a host this site's compensation standard excludes and are pending a licensed survey, so they are labeled rather than requoted. ABOS offers subspecialty certification only in Orthopaedic Sports Medicine and Surgery of the Hand, so no musculoskeletal oncology board exists; that is the American Board of Orthopaedic Surgery's own subspecialty list. Burnout 44%, among the lowest, against an all-physician average of 49% — Medscape Physician Burnout & Depression Report 2024 (n=9,226, fielded July–October 2023). That report is paywalled and returns HTTP 402, so its specialty rows are read through three independent relays that agree on the edition, the instrument and every row: Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty) and Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout). Women practicing, 6.8% on 2024 data and still the lowest of any specialty: AAMC, 2025 Key Findings, https://www.aamc.org/data-reports/data/2025-key-findings, where the all-physician share is 38.7%. Women residents, 23.9%: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf. DO and IMG: NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf, gives orthopaedic surgery 963 positions offered and 963 filled, with a Table 2 row of 765 MD seniors, 53 MD graduates, 121 DO seniors, 14 DO graduates, 5 U.S. IMGs and 5 non-U.S. IMGs, whose applicant-type columns sum to the 963 filled. Swept 2026-08-17: 1.0% IMG, about ten matches of 963, and 12.6% DO seniors or 14.0% counting DO graduates, all against the same 963 positions. This page said "single-digit IMG matches per year" in four places — the dashboard, the training bullet, the demographics bullet and the FLI risk bullet — while this footnote already carried the arithmetic that refutes it. It also carried "13–14% DO" in four places, which reads as a measurement range and is not one: 13% and 14% are the seniors-only and seniors-plus-graduates cuts of one Table 2 row, so both now travel with their denominator. The five-year DO-senior series is flat rather than rising, 12.6% (2026) · 14.1% (2025) · 12.8% (2024) · 13.2% (2023) · 12.7% (2022), with the most recent move downward. Women practicing was carried as "about 6%" in the FLI section against the 6.8% recorded here, and now reads 6.8%. ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²
Orthopedic fellowship match by degree and gender. "Orthopaedic Fellowship Match: How Do Degree and Gender Type Affect Match Rates?", JBJS Open Access, 2025, analyzing SF Match data 2012–2023 — 7,128 US-based applicants (3,058 international graduates excluded); 939 female (13%) and 6,093 male (87%); 1,028 osteopathic (14%) and 6,100 allopathic (86%); mean match rates 90% ± 6% for women and 90% ± 4% for men; 82% ± 8% for osteopathic applicants against 91% ± 3% for allopathic; the six subspecialties analyzed were trauma, sports medicine, foot and ankle, pediatrics, adult reconstruction, and shoulder and elbow, so musculoskeletal oncology is not separately reported. The authors conclude that men and women match at equal rates and that osteopathic graduates are consistently ranked lower. https://pmc.ncbi.nlm.nih.gov/articles/PMC12002389/ ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵

Researched with AI assistance and reviewed by hand. How this site is made